Over the past decade, robotic neurorehabilitation has become one of the most discussed innovations in neurological recovery. Robotic gait trainers, upper-limb rehabilitation systems, exoskeletons, and AI-assisted rehabilitation devices are increasingly being adopted by hospitals and rehabilitation centres worldwide. However, an important question remains: Are robots the future of neurorehabilitation—or are they simply another tool in the rehabilitation toolbox? As clinicians and researchers, we must move beyond marketing claims and focus on scientific evidence, patient selection, and clinical reasoning. What is Robotic Neurorehabilitation? Robotic neurorehabilitation involves the use of electromechanical devices that assist, guide, resist, or augment movement during therapy. These technologies include: • Robotic gait trainers • Wearable exoskeletons • Upper limb robotic rehabilitation devices • End-effector robotic systems • Sensor-based rehabilitation platforms • AI-assiste...
Purinergic
transmission is a fundamental signaling mechanism in the nervous system that
involves the release and action of purines, such as adenosine triphosphate
(ATP) and adenosine, as neurotransmitters. Here is an overview highlighting the
molecular basis of purinergic transmission:
1. Purinergic
Receptors:
o P2X Receptors: Ligand-gated
ion channels activated by ATP, leading to cation influx (e.g., Ca2+, Na+). P2X
receptors play a role in fast excitatory neurotransmission.
o P2Y Receptors: G
protein-coupled receptors activated by ATP or other nucleotides, triggering
intracellular signaling cascades. P2Y receptors are involved in modulating
synaptic transmission and neuronal excitability.
o Adenosine
Receptors: A1, A2A,
A2B, and A3 adenosine receptors are G protein-coupled receptors activated by
adenosine. They regulate neuronal activity, synaptic plasticity, and
neuroprotection.
2. ATP Release
Mechanisms:
o Exocytosis: ATP can be
released from synaptic vesicles via exocytosis in a calcium-dependent manner,
similar to classical neurotransmitters.
o Non-vesicular
Release: ATP can
also be released through connexin hemichannels, pannexin channels, and other
mechanisms in a calcium-independent manner, contributing to volume
transmission.
3. Enzymes and
Transporters:
o Ectonucleotidases: Enzymes like
CD39 and CD73 regulate the extracellular levels of ATP and adenosine by
hydrolyzing ATP to adenosine.
o Equilibrative
Nucleoside Transporters (ENTs): Facilitate the reuptake of adenosine into cells, regulating its
extracellular concentration and signaling duration.
4. Roles in the
Nervous System:
o Neurotransmission: ATP and
adenosine act as neurotransmitters and neuromodulators, influencing synaptic
transmission, plasticity, and neuronal excitability.
o Neuroprotection: Adenosine,
through A1 receptors, can exert neuroprotective effects by reducing
excitotoxicity and inflammation in the brain.
oPain Modulation: Purinergic
signaling is involved in pain processing, with ATP acting as a pain mediator
and adenosine as an analgesic agent.
5. Pathophysiological
Implications:
o Neurological
Disorders:
Dysregulation of purinergic transmission is implicated in various neurological
disorders, including epilepsy, neurodegenerative diseases, and chronic pain
conditions.
o Therapeutic
Targets:
Purinergic receptors and signaling pathways are potential targets for drug
development in the treatment of neurological and neuropsychiatric disorders.
Understanding the
molecular basis of purinergic transmission provides insights into the complex
mechanisms underlying neuronal communication and synaptic function. By
elucidating the roles of purinergic signaling in health and disease,
researchers can uncover novel therapeutic strategies for targeting purinergic
receptors and modulating purinergic transmission in neurological conditions.
Comments
Post a Comment